Company intelligence / Profile preview

Progen Pharmaceuticals

Melbourne, Victoria, Australiatheprogen.com ↗

Ownership: Private
Development stage: Commercial

Overview

Progen Pharmaceuticals was an Australian biotech company focused on novel oncology therapeutics targeting polyamine metabolism and epigenetic regulation. It expanded its pipeline through the acquisition of CellGate Inc., adding preclinical and early clinical-stage compounds. In 2015 it rebranded as TBG Diagnostics Ltd and shifted focus to commercializing molecular diagnostic kits and instruments serving clinical labs worldwide. The original drug development programs are no longer active under the "Progen" name.

Therapeutic areas: OncologyRare DiseasesImmunologyInfectious Diseases
Modalities: Small moleculeDiagnostic kits and instruments
Industry: Molecular Diagnostics

Partnerships

CellGate Inc. acquisition added scientific leadership/assets in oncology research.

Beyond the preview

Go deeper on Progen Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Progen Pharmaceuticals.

Explore the full profile